Pentamethylquercetin protects against diabetes-related cognitive deficits in diabetic goto-kakizaki rats

Journal of Alzheimer's Disease

Volumn 34, Issue 3, 2013, Pages 755-767

  Li, Xian Hui ^a,b   Xin, Xin ^a,c   Wang, Yan ^a   Wu, Jian Zhao ^a,c   Jin, Zhen Dong ^a,c   Ma, Li Na ^a,c   Nie, Chun Jie ^a,c   Xiao, Xiao ^a,c   Hu, Yan ^a,c   Jin, Man Wen ^a,c,d  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b JISHOU UNIVERSITY   (China)

^c Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province   (China)

^d Centre for Biomedicine Research   (China)

Author keywords

Akt cAMP response element binding protein pathway; cognitive deficits; dendrite; diabetes; pentamethylquercetin

Indexed keywords

ANTIDIABETIC AGENT; GLUTAMATE RECEPTOR 1; METFORMIN; PENTAMETHYLQUERCETIN; PROTEIN KINASE B; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; COGNITIVE DEFECT; CONTROLLED STUDY; DENDRITIC SPINE; DIABETES INDUCED COGNITIVE DYSFUNCTION; DIABETES MELLITUS; DRUG EFFICACY; GOTO KAKIZAKI RAT; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LEARNING; MALE; MEMORY; METABOLIC DISORDER; NERVE CELL; NERVE CELL LESION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT;

EID: 84876397853     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122017     Document Type: Article

References (47)

1. Maher PA, Schubert DR (2009) Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother 9, 617-630.
2. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5, 64-74. (Pubitemid 41790697)
3. Kopf D, Frolich L (2009) Risk of incident Alzheimer's disease in diabetic patients: A systematic review of prospective trials. J Alzheimers Dis 16, 677-685.
4. Yaffe K, Middleton LE, Lui LY, Spira AP, Stone K, Racine C, Ensrud KE, Kramer JH (2011) Mild cognitive impairment, dementia, and their subtypes in oldest oldwomen. Arch Neurol 68, 631-636.
5. Kim B, Feldman EL (2012) Insulin resistance in the nervous system. Trends Endocrinol Metab 23, 133-141.
6. Flood JF,Mooradian AD, Morley JE (1990) Characteristics of learning and memory in streptozocin-induced diabetic mice. Diabetes 39, 1391-1398. (Pubitemid 20372228)
7. Popovic M, Biessels GJ, Isaacson RL, Gispen WH (2001) Learning and memory in streptozotocin-induced diabetic rats in a novel spatial/object discrimination task. Behav Brain Res 122, 201-207. (Pubitemid 32396775)
8. Moreira T, Malec E, Ostenson CG, Efendic S, Liljequist S (2007) Diabetic type 2 goto-kakizaki rats show progressively decreasing exploratory activity and learning impairments in fixed and progressive ratios of a lever-press task. Behav Brain Res 180, 28-41. (Pubitemid 46661010)
9. Jeon BT, Jeong EA, Shin HJ, Lee Y, Lee DH, Kim HJ, Kang SS, Cho GJ, Choi WS, Roh GS (2012) Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 61, 1444-1454.
10. Martinez-Tellez R, Gomez-Villalobos MJ, Flores G (2005) Alteration in dendritic morphology of cortical neurons in rats with diabetes mellitus induced by streptozotocin. Brain Res 1048, 108-115. (Pubitemid 40803504)
11. Stranahan AM, Norman ED, Lee K, Cutler RG, Telljohann RS, Egan JM, Mattson MP (2008) Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18, 1085-1088.
12. Stranahan AM, Lee K, Martin B, Maudsley S, Golden E, Cutler RG, Mattson MP (2009) Voluntary exercise and caloric restriction enhance hippocampal dendritic spine density and BDNF levels in diabetic mice. Hippocampus 19, 951-961.
13. Benito E, Barco A (2010) CREB's control of intrinsic and synaptic plasticity: Implications for Creb-dependent memory models. Trends Neurosci 33, 230-240.
14. Fan N, Yang H, Zhang J, Chen C (2010) Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo delta9-thc exposure-impaired hippocampal synaptic plasticity. J Neurochem 112, 691-702.
15. Lu J,Wu DM, Zheng ZH, Zheng YL, Hu B, Zhang ZF (2011) Troxerutin protects against high cholesterol-induced cognitive deficits in mice. Brain 134, 783-797.
16. Sakamoto K, Karelina K, Obrietan K (2011) CREB: A multifaceted regulator of neuronal plasticity and protection. J Neurochem 116, 1-9.
17. Yiu AP, Rashid AJ, Josselyn SA (2011) Increasing CREB function in the ca1 region of dorsal hippocampus rescues the spatial memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacol 36, 2169-2186.
18. Li RW, Theriault AG, Au K, Douglas TD, Casaschi A, Kurowska EM,Mukherjee R (2006) Citrus polymethoxylated flavones improve lipid and glucose homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. Life Sci 79, 365-373. (Pubitemid 44172805)
19. Lee YS, Cha BY, Saito K, Yamakawa H, Choi SS, Yamaguchi K, Yonezawa T, Teruya T, Nagai K,Woo JT (2010) Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice. Biochem Pharmacol 79, 1674-1683.
20. Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A, St-Pierre P, Marette A, Huff MW (2011) Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes 60, 1446-1457.
21. Lin N, Sato T, Takayama Y, Mimaki Y, Sashida Y, Yano M, Ito A (2003) Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol 65, 2065- 2071. (Pubitemid 36629589)
22. Nagase H, Omae N, Omori A, Nakagawasai O, Tadano T, Yokosuka A, Sashida Y, Mimaki Y, Yamakuni T, Ohizumi Y (2005) Nobiletin and its related flavonoids with cre-dependent transcription-stimulating and neuritegenic activities. Biochem Biophys Res Commun 337, 1330-1336. (Pubitemid 41505268)
23. Onozuka H, Nakajima A, Matsuzaki K, Shin RW, Ogino K, Saigusa D, Tetsu N, Yokosuka A, Sashida Y, Mimaki Y, Yamakuni T, Ohizumi Y (2008) Nobiletin, a citrus flavonoid, improves memory impairment and Aβ pathology in a transgenic mouse model of alzheimer's disease. J Pharmacol Exp Ther 326, 739-744.
24. Yamakuni T, Nakajima A, Ohizumi Y (2010) Preventive action of nobiletin, a constituent of aurantii nobilis pericarpium with anti-dementia activity, against amyloidbeta peptide-induced neurotoxicity expression and memory impairment. Yakugaku Zasshi 130, 517-520.
25. Duenas M, Gonzalez-Manzano S, Gonzalez-Paramas A, Santos-Buelga C (2010) Antioxidant evaluation of o-methylated metabolites of catechin, epicatechin and quercetin. J Pharm Biomed Anal 51, 443-449.
26. Yoon JH, Lim TG, Lee KM, Jeon AJ, Kim SY, Lee KW (2011) Tangeretin reduces ultraviolet b (UVB)-induced cyclooxygenase-2 expression in mouse epidermal cells by blocking mitogen-activated protein kinase(MAPK)activation and reactive oxygen species (ROS) generation. J Agric Food Chem 59, 222-228.
27. Matsuzaki K, Yamakuni T, Hashimoto M, Haque AM, Shido O, Mimaki Y, Sashida Y, Ohizumi Y (2006) Nobiletin restoring beta-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. Neurosci Lett 400, 230-234.
28. Santos AC, Uyemura SA, Lopes JL, Bazon JN, Mingatto FE, Curti C (1998) Effect of naturally occurring flavonoids on lipid peroxidation and membrane permeability transition in mitochondria. Free Radic Biol Med 24, 1455-1461. (Pubitemid 28270347)
29. Shen JZ, Ma LN, Han Y, Liu JX, Yang WQ, Chen L, Liu Y, HuY, Jin MW(2012) Pentamethylquercetin generates beneficial effects in monosodium glutamate-induced obese mice and c2c12 myotubes by activating amp-activated protein kinase. Diabetologia 55, 1836-1846.
30. Wang Y, Xin X, Jin Z, Hu Y, Li X, Wu J, Jin M (2011) Anti-diabetic effects of pentamethylquercetin in neonatally streptozotocin-induced diabetic rats. Eur J Pharmacol 668, 347-353.
31. Chen L, He T, Han Y, Sheng JZ, Jin S, Jin MW (2011) Pentamethylquercetin improves adiponectin expression in differentiated 3T3-L1 cells via a mechanism that implicates PPARgamma together with TNF-alpha and IL-6. Molecules 16, 5754-5768.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,TurnerRC(1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419. (Pubitemid 15018832)
33. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11, 47-60. (Pubitemid 14088970)
34. Vorhees CV, Williams MT (2006) Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1, 848-858.
35. Sharma B, Singh N (2011) Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology (Berl) 215, 677-687.
36. Meijering E (2010) Neuron tracing in perspective. Cytometry A77, 693-704.
37. Kroner Z (2009) The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern Med Rev 14, 373-379.
38. Jones A, Kulozik P, Ostertag A, Herzig S (2009) Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J Alzheimers Dis 16, 787-808.
39. Frisardi V, Solfrizzi V, Capurso C, Imbimbo BP, Vendemiale G, Seripa D, Pilotto A, Panza F (2010) Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? J Alzheimers Dis 21, 57-63.
40. Porter DW, Irwin N, Flatt PR, Holscher C, Gault VA (2011) Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur J Pharmacol 650, 688-693.
41. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254. (Pubitemid 44137951)
42. Tahara A, Matsuyama-Yokono A, Shibasaki M(2011) Effects of antidiabetic drugs in high-fat diet and streptozotocinnicotinamide- induced type 2 diabetic mice. Eur J Pharmacol 655, 108-116.
43. van der Heide LP, Ramakers GM, Smidt MP (2006) Insulin signaling in the central nervous system: Learning to survive. Prog Neurobiol 4, 205-221. (Pubitemid 44331498)
44. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 15, 1807-1821.
45. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, Vendemiale G, Pilotto A, Panza F (2010) Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 9, 399-417.
46. Solas M, Aisa B, Mugueta MC, Del RJ, Tordera RM, Ramirez MJ (2010) Interactions between age, stress and insulin on cognition: Implications for Alzheimer's disease. Neuropsychopharmacol 35, 1664-1673.
47. de la Monte SM, Re E, Longato L, Tong M (2012) Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. J Alzheimers Dis 30(Suppl 2), S217-S229.